Description
A PHASE 3, MULTI CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERLY ACTIVE CROHN's DISEASE
Location: PAMF (Peninsula/South Bay)
Please contact: Elizabeth Jameiro jameire@sutterhealth.org about study Celgene Maintenance 3203
View study details on ClinicalTrials.govPrincipal Investigator
Recruitment Status
Active, Recruiting
Start Date
May 06, 2019
Related Studies
Transforming Primary and Specialty Care for Inflammatory Bowel Disease
Investigator: Alice R. Pressman, Ph.D., M.S.